- Home
- AXS vs JAZZ Comparison
AXS vs JAZZ Comparison
Compare AXS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXS
- JAZZ
- Stock Information
- Founded
- AXS 2001
- JAZZ 2003
- Country
- AXS Bermuda
- JAZZ Ireland
- Employees
- AXS N/A
- JAZZ N/A
- Industry
- AXS Property-Casualty Insurers
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- AXS Finance
- JAZZ Health Care
- Exchange
- AXS Nasdaq
- JAZZ Nasdaq
- Market Cap
- AXS 7.7B
- JAZZ 8.4B
- IPO Year
- AXS N/A
- JAZZ 2007
- Fundamental
- Price
- AXS $99.52
- JAZZ $139.47
- Analyst Decision
- AXS Strong Buy
- JAZZ Strong Buy
- Analyst Count
- AXS 9
- JAZZ 13
- Target Price
- AXS $100.25
- JAZZ $187.15
- AVG Volume (30 Days)
- AXS 844.3K
- JAZZ 1.3M
- Earning Date
- AXS 04-30-2025
- JAZZ 04-30-2025
- Dividend Yield
- AXS 1.79%
- JAZZ N/A
- EPS Growth
- AXS 207.21
- JAZZ 41.75
- EPS
- AXS 12.35
- JAZZ 8.65
- Revenue
- AXS $5,957,651,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- AXS N/A
- JAZZ $7.30
- Revenue Next Year
- AXS $7.74
- JAZZ $4.01
- P/E Ratio
- AXS $7.95
- JAZZ $15.63
- Revenue Growth
- AXS 5.57
- JAZZ 6.12
- 52 Week Low
- AXS $60.45
- JAZZ $99.06
- 52 Week High
- AXS $100.17
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- AXS 68.99
- JAZZ 57.68
- Support Level
- AXS $93.76
- JAZZ $137.74
- Resistance Level
- AXS $96.30
- JAZZ $142.64
- Average True Range (ATR)
- AXS 2.04
- JAZZ 3.15
- MACD
- AXS 0.46
- JAZZ -0.20
- Stochastic Oscillator
- AXS 94.07
- JAZZ 81.16
About AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a property and casualty insurance company that provides various products and services to clients and distribution partners. The company has operating subsidiaries and branch networks based in Bermuda, the United States, Canada, Europe, and Singapore. Its business consists of two distinct global underwriting platforms, AXIS Insurance, and AXIS Reinsurance. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.